1. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary 
Terry A. Jacobson, MD, Matthew K. Ito, PharmD, Kevin C. Maki, PhD, Carl E. Orringer, MD, Harold E. Bays, MD, Peter H. Jones, MD, James M. McKenney, PharmD, Scott M. Grundy, MD, PhD, Edward A. Gill, MD, Robert A. Wild, MD, PhD, Don P. Wilson, MD, W. Virgil Brown, MD 
Journal of Clinical Lipidology 
Volume 8, Issue 5, Pages (September 2014)
DOI: /j.jacl
Copyright © 2014 National Lipid Association Terms and Conditions

2. Figure 2
Progression of atherogenic cholesterol-lowering drug therapy. ∗A moderate- or high-intensity statin should be first-line drug therapy for treatment of elevated levels of atherogenic cholesterol, unless contraindicated. In a patient with very high triglycerides (≥500 mg/dL), a triglyceride-lowering drug may be considered for first-line use to prevent pancreatitis. Other atherosclerotic cardiovascular disease risk factors should be managed appropriately in parallel. †In most cases, goal levels should be achieved in approximately 6 months.
Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl )
Copyright © 2014 National Lipid Association Terms and Conditions